LOGIN
User Name:
Password:
Remember me   Forgot password?

Alexion Pharmaceuticals, Inc. (ALXN)

Health Care
Biotechnology

Rating:
Rating Since: 03/10/2009
Grade

66.9

Top-Down

SectorNEGATIVE
IndustryPOSITIVE
SentimentPOSITIVE
FundamentalBUY

 
Growth
Market Growth LT
Market Growth ST
Rel. Price Strength
Growth Potential
Earnings Momentum
Earnings Surprise
Value
Capital Structure
P/E Analysis
Price/Book Ratio
Price/Cash Flow Ratio
Price/Sales Ratio
Market Value
Profitability
Asset Utilization
Capital Utilization
Operating Margins
Relative Margins
Return on Equity
Quality of Revenues
Cash Flow
Cash Flow Growth
EBITDA Margin
Debt/Cash Flow Ratio
Interest Cov. Capacity
Economic Value
Retention Rate
Second Quarter (FY 2012)
64.21
Qtr End Date 06/30/2012
Report Date 07/25/2012
Estimate $0.37
Reported EPS $0.47
Surprise $0.1/27.03%
Impact $6.97
Snapshot Date 07/31/2012
Next Report Date 10/24/2012
 
A-
A
A-
N/A
A
A-
A-
Revenue (Q): $271.77M
Change: 44.42%
Net Income (Q): $36.26M
Change: 4.35%
EPS Estimate: $0.37
EPS Reported: $0.47
EPS Surprise: 27.03%
C
A
F
F
F
B
F
P/E (trailing): 103.55
P/Book (tangible): 25.24
P/Cash Flow: 62.35
P/Sales: -0.75
B
B+
D
A
A+
D
F
A
B+
B+
A+
A+
B+
A+
Cash Flow (Q): $101.53M
Change: %
Debt/CF: 0.00
ROIC: 16.57
TCE: 4.55
TCD: 0.15
TCC: 4.70
EVA: 11.87
Third Quarter (FY 2012)
67.66
Qtr End Date 09/30/2012
Report Date 10/24/2012
Estimate $0.47
Reported EPS $0.6
Surprise $0.13/27.66%
Impact -$5.68
Snapshot Date 10/30/2012
Next Report Date 02/14/2013
 
A-
A
A+
N/A
A
D
A
Revenue (Q): $289.33M
Change: 39.53%
Net Income (Q): $92.18M
Change: 40.58%
EPS Estimate: $0.47
EPS Reported: $0.6
EPS Surprise: 27.66%
B
A
A+
C
F
B
F
P/E (trailing): 84.30
P/Book (tangible): 19.75
P/Cash Flow: 48.33
P/Sales: -0.65
B
B+
D
A
A+
D
D
A
A+
A-
A+
A+
B+
A+
Cash Flow (Q): $141.32M
Change: %
Debt/CF: 0.41
ROIC: 15.83
TCE: 5.09
TCD: 0.17
TCC: 5.26
EVA: 10.57
Fourth Quarter (FY 2012)
65.67
Qtr End Date 12/31/2012
Report Date 02/14/2013
Estimate $0.54
Reported EPS $0.6
Surprise $0.06/11.11%
Impact -$8.62
Snapshot Date 02/19/2013
Next Report Date 04/25/2013
 
B+
F
A+
N/A
A
D
A
Revenue (Q): $316.54M
Change: 38.39%
Net Income (Q): $80.97M
Change: 68.09%
EPS Estimate: $0.54
EPS Reported: $0.6
EPS Surprise: 11.11%
B
A
A-
B-
D
B
F
P/E (trailing): 67.72
P/Book (tangible): 15.66
P/Cash Flow: 37.51
P/Sales: -0.92
B
A-
D
A
A+
D
D
A
A+
A-
A+
A+
B+
A+
Cash Flow (Q): $104.96M
Change: %
Debt/CF: 0.33
ROIC: 16.73
TCE: 4.91
TCD: 0.17
TCC: 5.08
EVA: 11.65
First Quarter (FY 2013)
69.92
Qtr End Date 03/31/2013
Report Date 04/25/2013
Estimate $0.6
Reported EPS $0.65
Surprise $0.05/8.33%
Impact $9.43
Snapshot Date 04/30/2013
Next Report Date 07/24/2013
 
B+
F
A+
N/A
A-
A
A-
Revenue (Q): $333.79M
Change: 37.02%
Net Income (Q): $82.22M
Change: 81.04%
EPS Estimate: $0.6
EPS Reported: $0.65
EPS Surprise: 8.33%
B
A
A+
B-
F
B
F
P/E (trailing): 68.04
P/Book (tangible): 16.38
P/Cash Flow: 43.08
P/Sales: -0.95
B
A-
D
A
A+
D
D
A
A+
A-
A+
A+
B
A+
Cash Flow (Q): $46.5M
Change: %
Debt/CF: 0.33
ROIC: 17.09
TCE: 7.23
TCD: 0.11
TCC: 7.34
EVA: 9.76
 
Start your 14 day FREE trial NOW!